Are you offering your people GLP-1s?

Download our whitepaper to find out how to build an employee benefits strategy that’s both effective – and sustainable.

The standardised, anonymised data we receive from our network covers our multinational clients’ employees and their dependants. It shows that 38% of claimants are living with at least one chronic condition, placing a growing health and financial burden on employees and their employers.

And despite more than one in four chronic disease claimants potentially being eligible for GLP-1s, only 5% of those are currently receiving these drugs.

Multinationals are faced with a real challenge: could covering GLP-1s for their people help address obesity and metabolic risk-related health issues across their workforce? What are the cost implications and how can they make sure the upfront investment leads to long-term improvements to employee health?

As GLP-1 spending rises in employee benefits programmes, our whitepaper explores how to answer these critical questions.

We are sharing our data and analysis to help multinationals create GLP-1 strategies that are effective now and into the future.

Download our whitepaper 'How can employers build an effective GLP-1 employee benefits strategy? Insights from MAXIS data' today

Three key trends

How can employers add GLP-1 medications to an employee benefits programme?

GLP-1 coverage varies significantly by market and insurer. Multinationals should work with their local insurance partners to understand applicable coverage rules, clinical eligibility criteria, prior-authorisation requirements, exclusions and continuation protocols in each market.

MAXIS+ clients can contact a MAXIS representative for information about covering GLP-1s in their employee benefits programme.

^{*MAXIS data covering GLP-1 patient utilisation patterns between 2020–2025.}